Tags

Type your tag names separated by a space and hit enter

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Adv Med Sci. 2014 Sep; 59(2):261-5.AM

Abstract

PURPOSE

This prospective, randomized, single-centre study compared peginterferons alfa-2a and alfa-2b, combined with ribavirin, in treating patients infected with hepatitis C virus (HCV) genotype 1.

MATERIAL/METHODS

Hundred-and-one patients received 48 weeks of open-label treatment with peginterferon alfa-2a (180 μg/week) and 111 patients received peginterferon alfa-2b (1.5 μg/kg/week). All patients received the same dose of ribavirin 1000/1200 mg/day, depending on weight. The primary efficacy endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA (<50 IU/mL) 24 weeks after the end of treatment.

RESULTS

Early virologic response (EVR), defined as at least 2 log₁₀ IU/mL reduction of viral load at 12 weeks, was more common in patients treated with peginterferon alfa-2a (88% vs. 74.8%; p=0.04). However, the difference in SVR was not statistically significant (49.5% vs. 44.1%; p=0.43).

CONCLUSIONS

Peginterferon alfa-2a treated patients were also more likely to be HCV RNA negative at the end of treatment (67.3% vs. 57.7%), but this difference did not reach statistical significance. Multivariate logistic regression analysis found that SVR was associated with low fibrosis stage (F1-2 by Scheuer; p=0.001) and low serum HCV RNA level (<400,000 IU/L; p=0.023). While both forms of peginterferon showed similar efficacy as measured by SVR, use of peginterferon alfa-2b could lower the number of patients receiving unnecessary treatment beyond 12 weeks.

Authors+Show Affiliations

Daily Department, Hospital of Infectious Diseases, Warsaw, Poland.Department of Immunopathology of Infectious and Parasitic Diseases, Warsaw Medical University, Warsaw, Poland.Daily Department, Hospital of Infectious Diseases, Warsaw, Poland.Daily Department, Hospital of Infectious Diseases, Warsaw, Poland.Department of Molecular Diagnostics, Hospital of Infectious Diseases, Warsaw, Poland.Department of Pathomorphology, Medical Center for Postgraduate Education, Warsaw, Poland.Department of Pathomorphology, National Institute of Hygiene, Warsaw, Poland.Daily Department, Hospital of Infectious Diseases, Warsaw, Poland; Department of Infectious Diseases for Adults, Warsaw Medical University, Warsaw, Poland. Electronic address: ahorban@zakazny.pl.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25117425

Citation

Berak, Hanna, et al. "Peginterferon Alfa-2a and Peginterferon Alfa-2b Combined With Ribavirin in Patients With Genotype 1 Chronic Hepatitis C: Results of a Prospective Single-centre Study." Advances in Medical Sciences, vol. 59, no. 2, 2014, pp. 261-5.
Berak H, Laskus T, Kołakowska-Rządzka A, et al. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study. Adv Med Sci. 2014;59(2):261-5.
Berak, H., Laskus, T., Kołakowska-Rządzka, A., Wasilewski, M., Stańczak, J. J., Bardadin, K., Walewska-Zielecka, B., & Horban, A. (2014). Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study. Advances in Medical Sciences, 59(2), 261-5. https://doi.org/10.1016/j.advms.2014.01.005
Berak H, et al. Peginterferon Alfa-2a and Peginterferon Alfa-2b Combined With Ribavirin in Patients With Genotype 1 Chronic Hepatitis C: Results of a Prospective Single-centre Study. Adv Med Sci. 2014;59(2):261-5. PubMed PMID: 25117425.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study. AU - Berak,Hanna, AU - Laskus,Tomasz, AU - Kołakowska-Rządzka,Anna, AU - Wasilewski,Marek, AU - Stańczak,Janusz J, AU - Bardadin,Krzysztof, AU - Walewska-Zielecka,Bożena, AU - Horban,Andrzej, Y1 - 2014/06/09/ PY - 2013/05/26/received PY - 2014/01/08/accepted PY - 2014/8/14/entrez PY - 2014/8/15/pubmed PY - 2015/8/20/medline KW - HCV KW - Interferon KW - Pegylated interferon KW - Ribavirin KW - Treatment SP - 261 EP - 5 JF - Advances in medical sciences JO - Adv Med Sci VL - 59 IS - 2 N2 - PURPOSE: This prospective, randomized, single-centre study compared peginterferons alfa-2a and alfa-2b, combined with ribavirin, in treating patients infected with hepatitis C virus (HCV) genotype 1. MATERIAL/METHODS: Hundred-and-one patients received 48 weeks of open-label treatment with peginterferon alfa-2a (180 μg/week) and 111 patients received peginterferon alfa-2b (1.5 μg/kg/week). All patients received the same dose of ribavirin 1000/1200 mg/day, depending on weight. The primary efficacy endpoint was sustained virologic response (SVR), defined as undetectable HCV RNA (<50 IU/mL) 24 weeks after the end of treatment. RESULTS: Early virologic response (EVR), defined as at least 2 log₁₀ IU/mL reduction of viral load at 12 weeks, was more common in patients treated with peginterferon alfa-2a (88% vs. 74.8%; p=0.04). However, the difference in SVR was not statistically significant (49.5% vs. 44.1%; p=0.43). CONCLUSIONS: Peginterferon alfa-2a treated patients were also more likely to be HCV RNA negative at the end of treatment (67.3% vs. 57.7%), but this difference did not reach statistical significance. Multivariate logistic regression analysis found that SVR was associated with low fibrosis stage (F1-2 by Scheuer; p=0.001) and low serum HCV RNA level (<400,000 IU/L; p=0.023). While both forms of peginterferon showed similar efficacy as measured by SVR, use of peginterferon alfa-2b could lower the number of patients receiving unnecessary treatment beyond 12 weeks. SN - 1898-4002 UR - https://www.unboundmedicine.com/medline/citation/25117425/Peginterferon_alfa_2a_and_peginterferon_alfa_2b_combined_with_ribavirin_in_patients_with_genotype_1_chronic_hepatitis_C:_results_of_a_prospective_single_centre_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1896-1126(14)00042-X DB - PRIME DP - Unbound Medicine ER -